Evidence map›Paper›PMID 36004889›Full record

ArticleBioengineering (Basel, Switzerland)2022

Naturally Equipped Urinary Exosomes Coated Poly (2-ethyl-2-oxazoline)-Poly (D, L-lactide) Nanocarriers for the Pre-Clinical Translation of Breast Cancer.

Jiang Ni, Yuanyuan Mi, Bei Wang, Yuting Zhu, Yang Ding, Yongjuan Ding, Xia Li

Open access · goldAbstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiang NiDepartment of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi 214000, China.
Yuanyuan MiDepartment of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi 214000, China.
Bei WangDepartment of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi 214000, China.
Yuting ZhuDepartment of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi 214000, China.
Yang DingCollege of Pharmacy, Pharmaceutical Series, China Pharmaceutical University, Nanjing 210000, China.
Yongjuan DingDepartment of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi 214000, China.
Xia LiDepartment of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi 214000, China.
Jiangnan University · CN

Funding

National Natural Science Foundation of China No.31801171the Top Talent Support Program for young and middle-aged people of Wuxi Health Committee No. HB2020039the Top Talent Support Program for young and middle-aged people of Wuxi Health Committee No. HB2020053the Wuxi Science and Technology Development Project No. N20202027
6 · The paper itself

Abstract

Recently, biomimetic nanoparticles for tumor-targeted therapy have attracted intensifying interest. Although exosomes are an excellent biomimetic material, numerous challenges are still hindering its clinical applications, such as low yield, insufficient targeting efficiency, and high cost. In this work, urinary exosomes (UEs) with high expression of CD9 and CD47 were extracted from breast cancer patients by a non-invasive method. Here, a nanotechnology approach is reported for tumor homologous targeting via CD9 and phagocytosis escape via CD47 through UE-coated poly (2-ethyl-2-oxazoline)-poly (D, L-lactide) (PEOz-PLA) nanoparticles (UEPP NPs). The cytotoxic agent doxorubicin (DOX)-loaded UEPP (UEPP-D) NPs with an initial particle size of 61.5 nm showed a burst release under acidic condition mimicking the tumor microenvironment. In vitro experiments revealed that UEPP-D NPs exhibited significantly improved cellular uptake, cytotoxicity, and apoptosis in MCF-7 cell lines as compared to DOX-loaded PEOz-PLA nanoparticles (PP-D NPs) and free DOX. More importantly, anti-phagocytosis and pharmacokinetic studies confirmed that UEPP-D NPs had superior immune escape ability and significantly prolonged the drug's bloodstream circulation in vivo. Finally, UEPP-D NPs showed a markedly higher antitumor efficacy and lower side-toxicity in MCF-7 tumor bearing nude mice model. Thus, this versatile nano-system with immune escape, homologous targeting, and rapid response release characteristics could be a promising tool for breast cancer treatment.

Indexed as

breast cancerdoxorubicinmembrane−coated biomimetic nanoparticlespoly (2−ethyl−2−oxazoline)−poly (D, L−lactide)urinary exosomes

Identifiers

PMID36004889
PMCPMC9404723
OpenAlexW4289705010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.